These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
187 related articles for article (PubMed ID: 8959319)
1. Characterization of the DD23 tumor-associated antigen for bladder cancer detection and recurrence monitoring. Marker Network for Bladder Cancer. Bonner RB; Liebert M; Hurst RE; Grossman HB; Bane BL; Hemstreet GP Cancer Epidemiol Biomarkers Prev; 1996 Dec; 5(12):971-8. PubMed ID: 8959319 [TBL] [Abstract][Full Text] [Related]
3. Evaluation of a new bladder tumor marker. Grossman HB; Liebert M; Sakakibara N; Wedemeyer GA; Stein JA; Washington RW Urol Clin North Am; 1991 Aug; 18(3):509-13. PubMed ID: 1877113 [TBL] [Abstract][Full Text] [Related]
4. Cellular F-actin levels as a marker for cellular transformation: correlation with bladder cancer risk. Rao JY; Hemstreet GP; Hurst RE; Bonner RB; Min KW; Jones PL Cancer Res; 1991 Jun; 51(11):2762-7. PubMed ID: 2032215 [TBL] [Abstract][Full Text] [Related]
5. [Tumor bladder antigen (TBA). A new method for the diagnosis and detection of recurrence of bladder cancer]. Escaf Barmadah S; Martín Benito JL; Fernández Gómez JM; San Martín Blanco A; Pérez Gracia FJ; Rodríguez Martínez JJ Arch Esp Urol; 1998 Mar; 51(2):129-36. PubMed ID: 9586309 [TBL] [Abstract][Full Text] [Related]
6. G-actin as a risk factor and modulatable endpoint for cancer chemoprevention trials. Hemstreet GP; Rao J; Hurst RE; Bonner RB; Waliszewski P; Grossman HB; Liebert M; Bane BL J Cell Biochem Suppl; 1996; 25():197-204. PubMed ID: 9027619 [TBL] [Abstract][Full Text] [Related]
7. Comparison of seven screening methods in the diagnosis of bladder cancer. Sun Y; He DL; Ma Q; Wan XY; Zhu GD; Li L; Luo Y; He H; Yang L Chin Med J (Engl); 2006 Nov; 119(21):1763-71. PubMed ID: 17097029 [TBL] [Abstract][Full Text] [Related]
8. Noninvasive diagnosis of bladder carcinoma by enzyme-linked immunosorbent assay detection of CD44 isoforms in exfoliated urothelia. Woodman AC; Goodison S; Drake M; Noble J; Tarin D Clin Cancer Res; 2000 Jun; 6(6):2381-92. PubMed ID: 10873090 [TBL] [Abstract][Full Text] [Related]
9. The relationship between serial measurements of the level of a bladder tumor associated antigen and the potential for recurrence. Blumenstein BA; Ellis WJ; Ishak LM J Urol; 1999 Jan; 161(1):57-60; discussion 60-1. PubMed ID: 10037368 [TBL] [Abstract][Full Text] [Related]
10. [ImmunoCyt--a new urine test in diagnosis of bladder cancer]. Feil G; Bichler KH; Päulgen-Nelde HJ; Hennenlotter J; Zumbrägel A; Stenzl A Urologe A; 2003 Apr; 42(4):531-7. PubMed ID: 12715125 [TBL] [Abstract][Full Text] [Related]
11. Comparative predictive values of urinary cytology, urinary bladder cancer antigen, CYFRA 21-1 and NMP22 for evaluating symptomatic patients at risk for bladder cancer. Sánchez-Carbayo M; Urrutia M; Silva JM; Romaní R; De Buitrago JM; Navajo JA J Urol; 2001 May; 165(5):1462-7. PubMed ID: 11342897 [TBL] [Abstract][Full Text] [Related]
12. Multiple biomarkers improve prediction of bladder cancer recurrence and mortality in patients undergoing cystectomy. Shariat SF; Karakiewicz PI; Ashfaq R; Lerner SP; Palapattu GS; Cote RJ; Sagalowsky AI; Lotan Y Cancer; 2008 Jan; 112(2):315-25. PubMed ID: 18008359 [TBL] [Abstract][Full Text] [Related]
13. Flow cytometric detection and quantitation of the epidermal growth factor receptor in comparison to Scatchard analysis in human bladder carcinoma cell lines. Brockhoff G; Hofstaedter F; Knuechel R Cytometry; 1994 Sep; 17(1):75-83. PubMed ID: 8001460 [TBL] [Abstract][Full Text] [Related]
14. Comparative evaluation of the diagnostic performance of the BTA stat test, NMP22 and urinary bladder cancer antigen for primary and recurrent bladder tumors. Giannopoulos A; Manousakas T; Gounari A; Constantinides C; Choremi-Papadopoulou H; Dimopoulos C J Urol; 2001 Aug; 166(2):470-5. PubMed ID: 11458049 [TBL] [Abstract][Full Text] [Related]
15. P21-activated kinase 1: a new molecular marker for intravesical recurrence after transurethral resection of bladder cancer. Ito M; Nishiyama H; Kawanishi H; Matsui S; Guilford P; Reeve A; Ogawa O J Urol; 2007 Sep; 178(3 Pt 1):1073-9. PubMed ID: 17644138 [TBL] [Abstract][Full Text] [Related]
16. Urinary cytology and quantitative BTA and UBC tests in surveillance of patients with pTapT1 bladder urothelial carcinoma. Babjuk M; Soukup V; Pesl M; Kostírová M; Drncová E; Smolová H; Szakacsová M; Getzenberg R; Pavlík I; Dvorácek J Urology; 2008 Apr; 71(4):718-22. PubMed ID: 18387400 [TBL] [Abstract][Full Text] [Related]
17. Markers of detection. Messing E Urol Oncol; 2007; 25(4):344-7. PubMed ID: 17628306 [TBL] [Abstract][Full Text] [Related]
18. Early diagnosis and monitoring of superficial transitional cell carcinoma by microsatellite analysis on urine sediment. Bartoletti R; Dal Canto M; Cai T; Piazzini M; Travaglini F; Gavazzi A; Rizzo M Oncol Rep; 2005 Mar; 13(3):531-7. PubMed ID: 15706429 [TBL] [Abstract][Full Text] [Related]